Sangamo Therapeutics, Inc. (SGMO) - Forward P/S Multiple

Corporate company logo of Sangamo Therapeutics Inc. (SGMO)

Sangamo Therapeutics (SGMO) profit potential relies on the licensing of zinc finger technologies and payments from industry behemoths. Drug development is automated using AI, although final tests require physician involvement. The forward price-to-sales valuation trend reflects current market dynamics, where 1.90 is the relevant value of the indicator. This chart highlights the company's strong scientific workforce and patent portfolio.

SGMO sangamo.com: Forward Price to Sales in the range 07/04/2022 - 05/09/2026

Financial and market metric breakdowns for Sangamo Therapeutics (SGMO)

- current price and projected stock value:
Initial company analysis:Sangamo Therapeutics Inc. (SGMO)
Original product of Sangamo BioSciences

Forward P/S measures market capitalization relative to expected sales volume, allowing investors to assess the degree of optimism priced in and the risk of overpaying for future earnings. The forward price-to-sales analysis for Sangamo Therapeutics (SGMO) accounts for the impact of "zinc finger" patent protection and prolonged regulatory cycles, confirming the fundamental resilience of the business through a balance of market expectations and technological barriers.

Competitors of Sangamo Therapeutics

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|intelliatx.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke STOK|biolifesolutions.com (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|Forward Price-to-Revenue Multiple Sionna Therapeutics, Inc. (SION)|Forward Price-to-Revenue Multiple PRME (Prime Medicine Bio)|Market Cap to Expected Sales Ratio Taysha|uniQure Pharma - Forward Price-to-Revenue Multiple|MeiraGTx Holdings plc - Price-to-Projected Revenue Ratio|regenxbio.com - Forward P/S Multiple|Solid Bio (SLDB) - Forward Price-to-Revenue Multiple|OCGN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Therapeutics)|Forward P/S Multiple RCKT|Price-to-Projected Revenue Ratio FDMT (4D Molecular Therapeutics Inc)|Forward P/S Multiple LXEO (Lexeo Therapeutics Inc.)|Forward Price to Sales KRRO|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Silence Therapeutics SLN|ProQR Therapeutics NV (PRQR) - Price-to-Projected Revenue Ratio|Codexis Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.